Sana Biotechnology Inc. (SANA) Bolsters Management Team

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best healthcare penny stocks to buy now. On September 5, the company confirmed the retirement of Executive Vice President Bernard J. Cassidy, effective October 20, 2025.

Sana Biotechnology Inc. (SANA) Bolsters Management Team

Likoper/Shutterstock.com

Mr. Cassidy is stepping down for personal reasons, and his retirement is not a result of any disagreement with the company regarding its policies, practices, or operations. Upon retiring, he is to provide transition-related service. The biotechnology company has already entered into an offer letter with Aaron M. Grossman, who is to take over as the executive vice president and chief legal officer.

Grossman joins as the company is making significant strides in the development of treatment for type 1 diabetes and other immune diseases. Its development practice is centered on the Hypoimmune (HIP) platform, which seeks to revolutionize the transplantation of engineered cells without triggering an immune response.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company focused on utilizing engineered cells as medicines for patients. Its ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.

While we acknowledge the potential of Sana Biotechnology, Inc. (NASDAQ:SANA) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SANA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.